The present invention relates to a replication retrovirus vector system comprising thymidine kinase (HSV-TK) gene and cytosine deaminase (CD) gene which make gene transfer to cancer cell tissue for the efficient treatment of cancer. Particularly, the HSV-TK/CD combined self-replicating retrovirus vector system of the present invention characteristically contains both HSV-TK and CD genes; has no worries about losing a therapeutic gene because recombination does not occur in this system during virus infection; and has an excellent stability, and also is able to induce cancer cell death by using the prodrug GCV or 5-FC and can apply a therapeutic gene or a prodrug thereof selectively to such cancer that shows resistance against cancer treatment using either TK or CD, so that this system of the invention can be advantageously used as a pharmaceutical composition for the treatment of cancer.

Disclosed are recombinant Newcastle disease virus (rNDV) vectors, related polynucleotides, and methods for eliciting an immune response against avian infectious bronchitis virus (IBV) or vaccinating against IBV.

Described herein are compositions for delivering a therapeutic or vaccine. Also described herein are methods for using the compositions described herein for delivering a therapeutic or a vaccine.

The invention pertains to new viral-like particles (VLPs), pharmaceutical compositions comprising the same and methods of using the same to prevent or treat an infection by a Coronaviridae virus. Advantageously, these VLPs can be used as a vaccine to be orally or nasally administrated.

The present invention relates to polypeptide for engineering integrase chimeric proteins and their use in gene therapy. In particular, the present invention relates to a polypeptide which comprises the amino acid sequence ranging from the amino acid residue at position 617 to the amino acid residue at position 622 in SEQ ID NO: 1 or a function conservative thereof.

The present invention relates to an expression vector, an expression cassette or a pseudotyped viral vector particle comprising at least one nucleic acid encoding at least one Koala Retrovirus (KoRV) Envelope glycoprotein (Env), related nucleic acids, pseudotyped viral vector particles, mammalian packaging cell lines, transduced mammalian cells as well as related methods and uses.

Disclosed herein are compositions, methods, kits, and systems relating to efficient delivery of cargos (e.g., therapeutic cargos) into cells, for instance, for in vivo delivery. The present disclosure provides lipid-containing particles (e.g., virus-like particles) for delivering therapeutic cargos. The present disclosure also provides polynucleotides encoding the lipid-containing particles provided herein, which may be useful for producing said lipid-containing particles. Also provided are methods for editing nucleic acid molecules in cells using the lipid-containing particles provided herein, as well as cells and kits comprising the lipid-containing particles.

The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.

Covalently-linked DNA polymerases are provided.

The present disclosure provides virus-like particles (VLPs) for delivering prime editors, and systems comprising such prime editor (PE) VLPs. The present disclosure also provides polynucleotides encoding the PE-VLPs described herein, which may be useful for producing said PE-VLPs. Also provided herein are methods for editing the genome of a target cell by introducing the presently described PE-VLPs into the target cell. The present disclosure also provides fusion proteins that make up a component of the PE-VLPs described herein, as well as polynucleotides, vectors, cells, and kits.